Aligos Therapeutics (NASDAQ:ALGS) Announces Quarterly Earnings Results, Beats Expectations By $0.95 EPS

Aligos Therapeutics (NASDAQ:ALGS) issued its quarterly earnings results on Thursday. The company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($1.09) by $0.95, FiscalAI reports. The firm had revenue of $27.78 million during the quarter, compared to analysts’ expectations of $24.68 million. Aligos Therapeutics had a negative return on equity of 139.47% and a negative net margin of 1,919.68%.

Aligos Therapeutics Stock Up 1.5%

Shares of NASDAQ ALGS traded up $0.08 during midday trading on Friday, hitting $5.59. 335,793 shares of the company’s stock were exchanged, compared to its average volume of 160,467. The firm has a market capitalization of $34.60 million, a PE ratio of -0.64 and a beta of 2.31. Aligos Therapeutics has a 12 month low of $3.98 and a 12 month high of $13.69. The company’s 50 day moving average price is $5.33 and its 200 day moving average price is $6.43.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on the stock. Weiss Ratings downgraded shares of Aligos Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, July 28th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Aligos Therapeutics in a research note on Friday, May 29th. Wall Street Zen raised shares of Aligos Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Sunday, May 17th. Finally, Lake Street Capital began coverage on shares of Aligos Therapeutics in a research note on Thursday, May 28th. They set a “buy” rating and a $45.00 price objective on the stock. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $38.50.

Hedge Funds Weigh In On Aligos Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Verition Fund Management LLC acquired a new stake in shares of Aligos Therapeutics during the 4th quarter worth about $664,000. Renaissance Technologies LLC boosted its holdings in shares of Aligos Therapeutics by 55.3% during the 4th quarter. Renaissance Technologies LLC now owns 85,444 shares of the company’s stock worth $796,000 after buying an additional 30,425 shares during the period. LPL Financial LLC grew its stake in Aligos Therapeutics by 19.7% in the 4th quarter. LPL Financial LLC now owns 66,000 shares of the company’s stock valued at $615,000 after buying an additional 10,880 shares during the last quarter. Two Sigma Investments LP grew its stake in Aligos Therapeutics by 223.0% in the 3rd quarter. Two Sigma Investments LP now owns 38,995 shares of the company’s stock valued at $382,000 after buying an additional 26,922 shares during the last quarter. Finally, Squarepoint Ops LLC raised its holdings in Aligos Therapeutics by 64.0% in the 3rd quarter. Squarepoint Ops LLC now owns 30,493 shares of the company’s stock valued at $299,000 after acquiring an additional 11,904 shares during the period. 60.43% of the stock is owned by institutional investors.

About Aligos Therapeutics

Aligos Therapeutics, Inc is a clinical‐stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics for chronic viral infections. The company leverages proprietary nucleic acid chemistry and small‐molecule discovery platforms to create therapies aimed at reducing viral replication, lowering antigen levels and restoring host immune function. Its pipeline includes both oligonucleotide conjugates and orally administered small molecules designed to address the root causes of persistent infections.

Founded in 2014 and headquartered in South San Francisco, California, Aligos advances its programs through strategic collaborations with academic institutions, research hospitals and industry partners.